Delivery Order SPE2DB20D3103-SPE2DB23FL8W6

Award Date 12/13/22
Potential Completion Date 12/14/22
Potential Value $24K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,843.23 firm fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with...
This federal contract award, valued at $12,230.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract involves the delivery of RESTASIS 0.05% eye emulsion 60s, a pharmaceutical product used for ophthalmic treatment. The contract is a delivery order that is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award, valued at $81,400.13, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product used in the treatment of dry eye disease. The award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, which has a ceiling value of $999,999,999 and runs through November...
This federal contract award, valued at $11,648.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of October 21, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $8,595.82, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $1,080.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to...
This federal contract award, valued at $8,638.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. The contract provides for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to...
This federal contract award, valued at $6,231.38, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of RESTASIS 0.05% EYE EMULSION 60S, a prescription eye medication, to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, with a ceiling value of $79,085.38, is for the delivery of RESTASIS 0.05% eye emulsion to support military healthcare programs. The award is a Delivery Order issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up...
This federal contract award, valued at $19,805.21, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Restasis 0.05% eye emulsion, a pharmaceutical product used in the treatment of dry eye disease. The contract is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FL8W6
    Delivery Order

This federal contract award, valued at $24,380.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used for the treatment of dry eye disease.

The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical worth up to $999,999,999.00. This single-award IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract does not have a set-aside designation, indicating it was awarded through full and open competition.

Generated 2/27/25, 10:52 AM